Pancreatic Cancer Research

ResearcherUniversity of LiverpoolNo recent work listed

Christos Dervenis

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5108218933. Sources: OpenAlex.

Their work

Papers
20 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
108
Papers, trials and grants by year

2014: 6 papers · 2015: 1 paper · 2016: 3 papers · 2017: none · 2018: 4 papers · 2019: 3 papers · 2020: none · 2021: 2 papers · 2022: 1 paper

Papers 20

  1. The Role of Inflammatory Markers in Predicting Resectability of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.21614/chirurgia.2603↗
  2. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. Co-author DOI 10.1136/jmedgenet-2020-106961↗
  3. Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers13020198↗
  4. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.32127↗
  5. The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000002557↗
  6. Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-paclitaxel-based chemotherapy or agents ta… Co-author DOI 10.1136/esmoopen-2019-000525↗
  7. Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Gr… Co-author DOI 10.1007/s11523-018-0605-y↗
  8. Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. Co-author DOI 10.1038/s41416-018-0004-2↗
  9. Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pa… Co-author DOI 10.1038/s41416-018-0005-1↗
  10. Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasms. Co-author DOI 10.1093/carcin/bgx150↗
  11. Positive para-aortic lymph nodes following pancreatectomy for pancreatic cancer. Systematic review and meta-analysis of impact on short term survival and assoc… Last author DOI 10.1016/j.hpb.2016.04.007↗
  12. Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicent… Co-author DOI 10.1016/j.surg.2016.02.019↗
  13. Expression Patterns of Growth and Survival Genes with Prognostic Implications in Advanced Pancreatic Cancer. Co-author DOI 10.21873/anticanres.11232↗
  14. Microvessel Landscape Assessment in Pancreatic Ductal Adenocarcinoma: Unclear Value of Targeting Endoglin (CD105) as Prognostic Factor of Clinical Outcome. Co-author DOI 10.1097/mpa.0000000000000197↗
  15. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to… Co-author DOI 10.1016/j.ejca.2014.07.011↗
  16. Economic Evaluation of NAB-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone for The Management of Metastatic Pancreatic Cancer in Greece. Co-author DOI 10.1016/j.jval.2014.08.2263↗
  17. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Co-author DOI 10.1016/j.surg.2014.02.001↗
  18. Extended pancreatectomy in pancreatic ductal adenocarcinoma: definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS). Co-author DOI 10.1016/j.surg.2014.02.009↗
  19. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic … Co-author DOI 10.1016/j.surg.2014.06.016↗
  20. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. Co-author DOI 10.1093/jnci/djt347↗

Closest collaborators

The 25 strongest of 108 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. John P. Neoptolemos · 9 shared papers, 2014–2019 · strength 0.38
  2. Christos Agalianos · 4 shared papers, 2016–2022 · strength 0.37
  3. Dimitrios G. Pectasides · 4 shared papers, 2016–2021 · strength 0.28
  4. George Fountzilas · 4 shared papers, 2016–2021 · strength 0.28
  5. George E. Pentheroudakis · 4 shared papers, 2014–2019 · strength 0.25
  6. Markus Wolfgang Büchler · 6 shared papers, 2014–2019 · strength 0.24
  7. Richard Charnley · 6 shared papers, 2014–2018 · strength 0.23
  8. Paula Ghaneh · 5 shared papers, 2014–2019 · strength 0.23
  9. Bengt L. G. Glimelius · 5 shared papers, 2014–2019 · strength 0.23
  10. Alan Anthoney · 4 shared papers, 2014–2019 · strength 0.20
  11. Attila Oláh · 4 shared papers, 2014–2019 · strength 0.20
  12. Daniel H. Palmer · 4 shared papers, 2014–2019 · strength 0.20
  13. Niall Christopher Tebbutt · 4 shared papers, 2014–2019 · strength 0.20
  14. Julia V. Mayerle · 4 shared papers, 2014–2019 · strength 0.20
  15. Juan W. Valle · 4 shared papers, 2014–2019 · strength 0.20
  16. Christopher Michael Halloran · 4 shared papers, 2014–2019 · strength 0.20
  17. Jakob Robert Izbicki · 5 shared papers, 2014–2019 · strength 0.20
  18. William Greenhalf · 4 shared papers, 2014–2018 · strength 0.20
  19. David Goldstein · 3 shared papers, 2018–2019 · strength 0.18
  20. Markus M. Lerch · 3 shared papers, 2018–2019 · strength 0.18
  21. George Zarkavelis · 2 shared papers, 2019–2021 · strength 0.16
  22. Claudio Bassi · 5 shared papers, 2014 · strength 0.15
  23. Eithne Costello · 3 shared papers, 2014–2018 · strength 0.14
  24. Mustapha Adham · 4 shared papers, 2014–2016 · strength 0.14
  25. Vasilios Karavasilis · 2 shared papers, 2018–2019 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.